Iontophoresis in the management of oral submucous fibrosis - a review

---

Authors

Sathya Sai Vigneshwari J¹ , Jayachandran Sadaksharam¹

1. Department of Oral Medicine and Radiology, Tamil Nadu Government Dental College and Hospital,Chennai

Conference / event

34th National Conference of Indian Academy of Oral Medicine and Radiology, December 2023 (Davangere, Karnataka, India)

Poster summary

Oral submucous fibrosis is a chronic, progressive, crippling disorder closely associated with areca nut chewing and characterized by fibro-elastic change leading to restricted mouth opening. Various medical management tried in the management of oral submucous fibrosis. One such management is Iontophoresis. Iontophoresis is the topical application of an ionized substance through soft tissue by the application of continuous direct electric current. Iontophoresis of dexamethasone sodium phosphate is used in the management of oral submucous fibrosis. The objective of this review is to evaluate iontophoresis in the management of oral submucous fibrosis. Intralesional injection of Dexamethasone sodium phosphate or hyaluronidase can cause patient discomfort. The short duration of topical co-iontophoresis of Dexamethasone sodium phosphate or other therapeutics to the mucosa increases local bioavailability and presents a patient-friendly treatment for the management of oral submucous fibrosis.

Keywords

Oral submucous Fibrosis, Dexamethasone, Iontophoresis, Local drug delivery, Topical therapy

Research areas

Medicine

References

1. Ragit R, Fulzele P, Rathi N V, et al. (October 25, 2022) Iontophoresis as an Effective Drug Delivery System in Dentistry: A Review. Cureus 14(10):e30658. DOI 10.7759/cureus.30658
2. Sadaksharam J, Mahalingam S. Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis - An Ultrasonographic Study. Contemp Clin Dent. 2017 Apr-Jun;8(2):200-204. doi: 10.4103/ccd.ccd_1192_16. PMID: 28839403; PMCID: PMC5551322.
3. Tyagi V, Serna-Jiménez CE, Kalia YN. Controlled simultaneous iontophoresis of buflomedil hydrochloride and dexamethasone sodium phosphate to the mucosa for oral submucous fibrosis. Int J Pharm. 2021 Sep 25;607:121009. doi: 10.1016/j.ijpharm.2021.121009. Epub 2021 Aug 12. PMID: 34391856.

Funding

No data provided

Supplemental files

No data provided

Additional information

Competing interests

No competing interests were disclosed.

Data availability statement

The datasets generated during and / or analyzed during the current study are available from the corresponding author on reasonable request.

Creative Commons license

Copyright © 2024 Vigneshwari J et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.